SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients

Type 2 diabetes can lead to diabetic kidney disease, but a class of drugs that cause the kidneys to remove glucose through urine has been gaining attention. An Osaka Metropolitan University-led research group has investigated how such drugs maintain kidney health.

Known as SGLT2 (sodium-glucose cotransporter-2) inhibitors, the drugs are used to treat type 2 diabetes along with an exercise and diet regimen. The group led by Graduate School of Medicine Associate Professor Katsuhito Mori focused on the SGLT2 inhibitor canagliflozin and its effects on the kidney.

Using BOLD (blood oxygenation level-dependent) MRI, a method used to see changes in blood oxygen flow in the brain to monitor activity, the group found that patients on canagliflozin for five days showed more oxygen in their kidneys the first day after administration of the drug. The researchers believe this indicates that SGLT2 inhibitors might improve the oxygenation of the kidneys, thereby protecting the organs.

In animal experiments, the amount of oxygen in the kidneys can be measured by inserting a microelectrode, but this is not possible in humans. BOLD MRI can measure kidney oxygenation non-invasively, and this is expected to become an important technology for elucidating the mechanisms of kidney disease for the development of therapeutic drugs."

Associate Professor Katsuhito Mori, Graduate School of Medicine, Osaka Metropolitan University

The findings were published in Frontiers in Endocrinology.